BioSpace News Archive

Allarity Therapeutics, Inc. announced that the Company’s adjourned 2022 Annual Stockholders Meeting set for December 2, 2022 has been cancelled and a new meeting date for the Annual Stockholders Meeting will be held, as a virtual meeting, on January 19, 2023.

Dallas Hack , MD, CEO of VirTech Bio , will present the advancements of OxyBridge™, a novel Hemoglobin-Based Oxygen Carrier (HBOC) solution for use when tissue oxygenation is required but blood is not an option (Patent 11504417, issued 11.22.22). Dr. Hack became CEO of VirTech Bio in March 2022.

Zentalis TM Pharmaceuticals, Inc. today announced that on December 1, 2022, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 204,850 shares of the Company’s common stock to seven newly hired employees.

Y-mAbs Therapeutics, Inc. announced that the U.S. Food and Drug Administration has issued a complete response letter for the Biologics License Application for the investigational medicine 131I-omburtamab for the treatment of CNS/leptomeningeal metastasis from neuroblastoma.

Minze Health announced that White Fund, Capricorn Partners and PMV have jointly invested €3.9 million in the company to fund its further growth and product development roadmap.

Halia Therapeutics, a clinical stage biopharmaceutical company advancing innovative medicines to treat diseases driven by chronic inflammation, was invited to present today at the 4th Inflammasome Therapeutics Summit.

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company”), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers is pleased to announce that it has completed the final engineering of IzoView.

Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it has received a Notice of Allowance for its US Patent Application 16/224,590 titled “Magnetic Resonance Spectroscopy System and Method for Diagnosing Pain or Infection Associated with Propionic Acid”.

Millstone Medical Outsourcing, the industry’s leading partner of choice for medical manufacturers’ post-manufacturing and aftermarket services, announces its completed acquisition of Ethide Labs on November 14, 2022.

Ventus Therapeutics, Inc. announced that its Head of In Vitro and In Vivo Pharmacology, Anick Auger, presented an overview of the company’s novel NLRP3 inhibitor programs at the Fourth Inflammasome Therapeutics Summit, held from Nov. 29 to Dec. 1 in Boston.